Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-04-01 Epub Date: 2024-01-17 DOI:10.2217/fon-2023-0858

Nicholas Robert, Connie Chen, Sindy Kim, Zhe Zhang, Kathleen M Aguilar, Yunfei Wang, Benjamin Li, Michael Gaffney, Xin Huang, Lynn McRoy

{"title":"Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.","authors":"Nicholas Robert, Connie Chen, Sindy Kim, Zhe Zhang, Kathleen M Aguilar, Yunfei Wang, Benjamin Li, Michael Gaffney, Xin Huang, Lynn McRoy","doi":"10.2217/fon-2023-0858","DOIUrl":null,"url":null,"abstract":"Aim: Provide real-world data on palbociclib as evidence of effectiveness in patient populations from routine clinical practice. Methods: This was a retrospective, observational cohort study of patients with HR+/HER2- metastatic breast cancer treated with palbociclib plus aromatase inhibitor (AI) or AI alone as first-line therapy within the US Oncology Network. Results: Patients treated with palbociclib plus AI (n = 838) versus AI alone (n = 450) had a numerically longer median overall survival (42.1 vs 35.7 months; hazard ratio [HR] = 0.90 [95% CI: 0.75-1.07]; p = 0.117) and a significantly extended real-world progression-free survival (21.0 vs 15.7 months; HR = 0.75 [95% CI: 0.64-0.88]; p = 0.0002) after normalized inverse probability treatment weighting. Conclusion: These real-world results support the use of palbociclib plus AI as first-line treatment in routine clinical practice for patients with HR+/HER2- metastatic breast cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"761-780"},"PeriodicalIF":3.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0858","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Provide real-world data on palbociclib as evidence of effectiveness in patient populations from routine clinical practice. Methods: This was a retrospective, observational cohort study of patients with HR+/HER2- metastatic breast cancer treated with palbociclib plus aromatase inhibitor (AI) or AI alone as first-line therapy within the US Oncology Network. Results: Patients treated with palbociclib plus AI (n = 838) versus AI alone (n = 450) had a numerically longer median overall survival (42.1 vs 35.7 months; hazard ratio [HR] = 0.90 [95% CI: 0.75-1.07]; p = 0.117) and a significantly extended real-world progression-free survival (21.0 vs 15.7 months; HR = 0.75 [95% CI: 0.64-0.88]; p = 0.0002) after normalized inverse probability treatment weighting. Conclusion: These real-world results support the use of palbociclib plus AI as first-line treatment in routine clinical practice for patients with HR+/HER2- metastatic breast cancer.

查看原文本刊更多论文

帕博西尼（palbociclib）联合芳香化酶抑制剂治疗HR+/HER2-转移性乳腺癌的实际效果比较。

目的：提供有关帕博西尼（palbociclib）的真实世界数据，作为常规临床实践中患者群体有效性的证据。研究方法这是一项回顾性、观察性队列研究，研究对象是在美国肿瘤网络内接受palbociclib联合芳香化酶抑制剂（AI）或单用AI作为一线疗法的HR+/HER2-转移性乳腺癌（mBC）患者。研究结果采用帕博西尼（palbociclib）联合芳香化酶抑制剂（AI）治疗的患者（n = 838）与单独使用AI治疗的患者（n = 450）相比，中位总生存期（42.1个月 vs 35.7个月；危险比[HR] = 0.90 [95% CI: 0.75-1.07]；p = 0.117）更长，归一化反概率治疗加权后的实际无进展生存期（21.0个月 vs 15.7个月；HR = 0.75 [95% CI: 0.64-0.88]；p = 0.0002）显著延长。结论这些实际结果支持将palbociclib加AI作为HR+/HER2-转移性乳腺癌患者常规临床实践中的一线治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.